Explore Our Diverse Range Of Offerings
From detailed reports to experts services offered in 15+ Industry Domains
Report
Press Release
Blogs
Industry Statistics
Add 2 More Reports For 20% off

Report Overview

Valley Fever, or Coccidioidomycosis, is an endemic systemic fungal infection caused by the dimorphic fungi Coccidioides immitis and Coccidioides posadasii. U.S. surveillance recorded 21,037 reported Valley Fever cases in 2023, while a 2025 CDC-led modelling study estimated that approximately 273,000 symptomatic incident infections occurred nationally in 2019, with a credible interval of 206,000-360,000. According to Valley Fever (Coccidioidomycosis) Epidemiology Forecast by Expert Market Research (EMR), the epidemiological measurement of Valley Fever differs from that of many communicable diseases because routine national surveillance captures only a fraction of symptomatic infections.

2025

Base Year

2019-2025

Historical Period

2026-2035

Forecast Period

Valley Fever (Coccidioidomycosis) – Number of Cases by Year

Read more about this report - Request a Free Sample

Valley Fever (Coccidioidomycosis) Epidemiology Forecast Report Coverage

Expert Market Research's “Valley Fever (Coccidioidomycosis) Epidemiology Forecast Report 2026-2035” offers comprehensive information on the prevalence and demographics of Valley Fever (Coccidioidomycosis). It projects the future incidence and prevalence rates of Valley Fever (Coccidioidomycosis) cases across various populations. The study covers age, gender, and type as major determinants of the Valley Fever (Coccidioidomycosis) population. The report highlights patterns in the prevalence of Valley Fever (Coccidioidomycosis) over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of Valley Fever (Coccidioidomycosis) in the 8 major markets.

Regions Covered

  • United States
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Japan
  • India

Valley Fever (Coccidioidomycosis) Understanding: Disease Overview

Valley Fever, or Coccidioidomycosis, is an endemic systemic fungal infection caused by the dimorphic fungi Coccidioides immitis and Coccidioides posadasii. Infection follows inhalation of airborne arthroconidia from disturbed soil and is concentrated in arid and semi-arid regions of the southwestern United States, with additional endemic areas in Mexico and parts of Central and South America. Most infections are pulmonary and self-limited, but a proportion progress to persistent pulmonary disease or disseminated infection involving the skin, bones, joints, lymph nodes, or central nervous system.

Key Report Insights

Parameter

Insight

Largest Patient Pool

United States

Fastest Growing Country

United States

High-Risk Population

People living or working in endemic regions, individuals exposed to dust or soil disruption, agricultural and outdoor workers, people with immunosuppression, pregnant women, and certain racial/ethnic populations including Filipinos and African Americans who have increased risk of severe or disseminated disease.

Key Diagnostic Method

Diagnosis combines Coccidioides-specific serology with fungal culture, histopathology, antigen detection or molecular testing according to clinical presentation. Culture and histopathology are particularly important when disseminated or atypical disease is suspected.

Major Risk Factor

Inhalation of airborne Coccidioides spores following environmental soil or dust exposure in endemic areas is the principal risk factor. Immunosuppression, pregnancy and certain host characteristics increase the risk of severe or disseminated disease.

Major gap in the market

Delayed recognition and inadequate testing remain major gaps because Valley Fever clinically resembles bacterial or viral pneumonia and tuberculosis. Limited national surveillance outside the U.S. further obscures the international burden.

Valley Fever (Coccidioidomycosis) Epidemiology Perspective

The Valley Fever (Coccidioidomycosis) epidemiology division offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for the Valley Fever (Coccidioidomycosis) epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for Valley Fever (Coccidioidomycosis) and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

Epidemiology Segment

Key Insights

Diagnosed Prevalent Cases of the Disease

Point prevalence is not a reliable measure because Valley Fever is generally an acute infection and many infections are never diagnosed. The United States reported 21,037 cases in 2023. CDC's 2025 modelling study estimated 206,000-360,000 symptomatic incident cases in 2019, demonstrating substantial under-ascertainment. India had seven laboratory-confirmed coccidioidomycosis cases among 893 proven endemic-mycotic cases identified in a systematic review covering 1960–August 2025.

Gender-Specific Cases of the Disease

In the Indian systematic review, all seven documented coccidioidomycosis patients were male, with a median age of 31 years (IQR 22–65). This is a literature-derived case distribution and should not be interpreted as a population sex ratio. U.S. epidemiology also demonstrates demographic variation by occupation, exposure and underlying host factors.

Age-Specific Cases of the Disease

Valley Fever occurs across the age spectrum. CDC surveillance indicates that reported U.S. rates are highest among people aged ≥60 years. In the Indian literature review, the seven documented cases had a median age of 31 years, reflecting the small, selected nature of published cases rather than population incidence.

Ethnicity-Wise Cases of the Disease

U.S. epidemiological studies identify increased risk of disseminated disease among certain racial and ethnic populations, particularly Filipinos and African Americans. These associations are not established as population-level risk estimates for the other 7MM countries and should not be extrapolated across national populations.

Mortality and Survival Analysis of the Disease

Most uncomplicated pulmonary infections resolve without mortality, but disseminated and CNS disease can be life-threatening. CDC's 2025 model estimated approximately 700-1,100 coccidioidomycosis-associated deaths in the U.S. in 2019. In the European systematic review, overall mortality among historical published cases was 7%, increasing to 24% among immunocompromised patients; these figures are based on cases published through 2022 rather than current population surveillance.

Type-Specific Disease Burden and Epidemiology Analysis

Disease Type

Prevalence

Primary Pulmonary Coccidioidomycosis

The commonest clinically recognized manifestation following inhalation of Coccidioides arthroconidia. It ranges from asymptomatic infection to an acute community-acquired-pneumonia-like illness with fever, cough, chest pain, fatigue and dyspnea.

Uncomplicated Pulmonary Coccidioidomycosis

Mild-to-moderate pulmonary disease that generally resolves with supportive management and clinical observation in otherwise healthy individuals. Some patients experience prolonged constitutional or respiratory symptoms despite microbiological control.

Chronic Pulmonary Coccidioidomycosis

Persistent pulmonary infection characterized by chronic symptoms and radiographic abnormalities such as nodules, cavities or progressive infiltrates. It may require prolonged antifungal therapy.

Cutaneous Coccidioidomycosis

Disseminated or, rarely, primary cutaneous disease involving the skin. Lesions can include papules, plaques, ulcers, nodules and draining lesions.

Valley Fever (Coccidioidomycosis) – Number of Cases by Country

Read more about this report - Request a Free Sample

Country-wise Valley Fever (Coccidioidomycosis) Epidemiology

The Valley Fever (Coccidioidomycosis) epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

Country

Key Insights

United States

CDC surveillance recorded 21,037 Valley Fever cases in 2023, including 10,990 in Arizona and 9,060 in California; these two states accounted for approximately 95% of reported U.S. cases. CDC's 2025 burden analysis estimated 273,000 symptomatic incident cases in 2019, with 206,000–360,000 as the 95% credible interval, 23,000 hospitalizations and approximately 900 deaths. The modeled burden therefore substantially exceeds routine surveillance.

Germany

A 2026 Robert Koch Institute-associated study identified 15 culture- or histology-confirmed travel-associated human cases diagnosed in Germany during 2011-2023. Ten were caused by C. posadasii and two by C. immitis; six had pulmonary disease, two CNS disease and three disseminated disease. Most infections originated from travel to Arizona. The study demonstrates established imported disease but not endemic German transmission.

France

France has documented imported coccidioidomycosis, primarily associated with travel or migration from endemic regions. A 2025 European systematic review identified 20 historical French cases through 2022, but no contemporary national surveillance denominator is available. The French burden therefore cannot be converted into a reliable 2023-2026 population incidence estimate.

Italy

Coccidioidomycosis remains rare in Italy and is predominantly imported. A systematic review of Italian endemic mycoses identified 10 published coccidioidomycosis cases, including infections acquired in the United States and South America, with no deaths reported among the cases reviewed. Because the underlying literature extended back decades, these data are not used as a contemporary national incidence estimate.

Spain

Spain has historically contributed the largest number of published European coccidioidomycosis cases. The 2025 European systematic review identified 96 cases from Spain among publications covering 1948-2022, largely associated with travel or migration. No national 2023-2026 surveillance series establishing a population incidence rate was identified.

United Kingdom

Coccidioidomycosis is rare in the United Kingdom and is principally encountered as an imported travel-associated infection. Contemporary UK population surveillance does not provide a dedicated national incidence series comparable with U.S. Valley Fever surveillance. European systematic evidence identifies travel and migration as the principal mechanisms through which cocci appears outside endemic areas.

Japan

Japan is a non-endemic setting in which coccidioidomycosis is principally travel-associated. A 2026 Japanese case report described chronic pulmonary coccidioidomycosis complicated by meningitis, illustrating the possibility of severe imported disease requiring prolonged antifungal management. No population-level Japanese incidence estimate for 2023-2026 was identified.

India

A 2026 systematic review of laboratory-confirmed endemic mycoses identified seven coccidioidomycosis cases among 893 proven endemic-mycotic cases reported from India through August 2025. The seven cases were reported from New Delhi (4), Karnataka (2), Andhra Pradesh (1) and Tamil Nadu (1); all seven documented patients were male, with a median age of 31 years. Coccidioidomycosis accounted for 0.8% of all proven endemic-mycotic cases in the review. The evidence remains case-based rather than population-based, consistent with rare imported disease and substantial potential underrecognition.

Key Market Gaps, Untapped Opportunities, and Emerging Growth Areas in the Regional Disease Epidemiology Landscape

The principal diagnostic challenge is clinical overlap with bacterial pneumonia, tuberculosis, and other fungal infections. In a 2025 enhanced-surveillance investigation in Riverside County, California, the median interval from the first healthcare encounter to coccidioidomycosis testing was 55 days. Among interviewed patients, 41.1% had received antibiotics, while 50.9% had been hospitalized, highlighting delays in diagnostic recognition even in highly endemic settings. Outside the United States, a 2025 European systematic review identified 197 published cases across 20 European countries from 1948–2022. Most cases were associated with migration or travel from endemic regions, and pulmonary disease predominated, while diagnostic delays reflected limited clinical familiarity.

Valley Fever (Coccidioidomycosis): Treatment Overview

Treatment depends on disease severity, host factors, and anatomical involvement. Mild uncomplicated pulmonary disease in immunocompetent patients may be observed, while symptomatic or progressive disease commonly requires oral azoles such as fluconazole or itraconazole. Severe pulmonary or disseminated disease may require amphotericin B followed by prolonged azole therapy. Coccidioidal meningitis generally requires prolonged, often indefinite, fluconazole therapy because relapse may occur after discontinuation. Osteoarticular, cutaneous, and disseminated disease may also require prolonged antifungal treatment and, in selected cases, surgery. Diagnosis combines exposure history with laboratory confirmation, including serology, culture, histopathology, and molecular testing, depending on presentation.

Key Questions Answered

  • What is the current and projected burden of Valley Fever (Coccidioidomycosis) across the 8 major markets?
  • Which countries across the 8 major markets account for the highest Valley Fever (Coccidioidomycosis) patient populations and fastest growth rates?
  • What is the diagnosed versus undiagnosed patient population of Valley Fever (Coccidioidomycosis) across key countries in the 8 major markets?
  • Which countries demonstrate the largest gaps in screening, early diagnosis, and disease awareness of Valley Fever (Coccidioidomycosis) across the 8 major markets?
  • What are the major drivers contributing to the increasing burden of Valley Fever (Coccidioidomycosis) across the 8 major markets?
  • How do major comorbidities and risk factors influence Valley Fever (Coccidioidomycosis) epidemiology trends across the 8 major markets?
  • What are the regional trends in advanced disease progression, treatment uptake, and patient management of Valley Fever (Coccidioidomycosis) across the 8 major markets?
  • Which patient segments represent the highest unmet clinical need in the Valley Fever (Coccidioidomycosis) landscape across the 8 major markets?
  • Which therapeutic areas linked to Valley Fever (Coccidioidomycosis) are expected to witness the strongest growth opportunities across the 8 major markets?
  • How is the Valley Fever (Coccidioidomycosis) epidemiology landscape expected to evolve over the next 5 to 10 years across the 8 major markets?
  • Which countries across the 8 major markets offer the most attractive market opportunities based on Valley Fever (Coccidioidomycosis) epidemiology and healthcare infrastructure?
  • Which epidemiological trends are expected to influence future drug development and market access strategies for Valley Fever (Coccidioidomycosis) across the 8 major markets?

Scope of the Valley Fever (Coccidioidomycosis) Epidemiology Report

  • The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of Valley Fever (Coccidioidomycosis) based on several factors.
  • Valley Fever (Coccidioidomycosis) Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
  • The Valley Fever (Coccidioidomycosis) report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

Related Reports

Oral Antibiotics Market

Bacterial Disease Diagnostics Market

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*

Report Summary

Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.

Key Highlights of the Report

Please note that the figures mentioned in the description serve as estimates and may vary from the actual figures presented in the final report.

Report Features

Details

Base Year

2025

Historical Period

2019-2025

Forecast Period

2026-2035

Epidemiology Statistics Provided

  • Diagnosed Prevalent Cases
  • Type-Specific Cases
  • Gender-Specific Cases
  • Age-Specific Cases

Segmentation Provided

  • Epidemiology by Age Group
  • Epidemiology by Gender
  • Epidemiology by Type of Disease
  • Epidemiology by Region

Geographies Covered

  • United States
  • Germany
  • Italy
  • France
  • Spain
  • United Kingdom
  • Japan
  • India

Datasheet

10 % Off

USD

2,699

2,429

Single User License

10 % Off

USD

4,299

3,869

Five User License

15 % Off

USD

5,799

4,949

Corporate License

15 % Off

USD

6,999

5,949

Datasheet

One User

USD 2,699

USD 2,429

tax inclusive*

  • Selected Segments
  • Printing Restrictions
  • Excel Spreadsheet Delivered via Email
  • Full Report
  • Periodic Updates
  • Post Sales Analysts Support
  • Unlimited Prints

Single User License

One User

USD 4,299

USD 3,869

tax inclusive*

  • All Segments
  • Printing Restrictions
  • PDF Delivered via Email
  • Custom Report Layout
  • Post Sales Analysts Support
  • Periodic Updates
  • Unlimited Prints

Five User License

Five User

USD 5,799

USD 4,949

tax inclusive*

  • All Segments
  • Five Prints Available
  • PDF Delivered via Email
  • Limited Free Customization
  • Post Sales Analyst Support
  • Custom Report Layout
  • Periodic Updates
  • Unlimited Prints

Corporate License

Unlimited Users

USD 6,999

USD 5,949

tax inclusive*

  • All Segments
  • Unlimited Prints Available
  • PDF & Excel Delivery via Email
  • Limited Free Customization
  • Post Sales Analysts Support
  • Discount On Next Update
  • Custom Report Layout

*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*

Bundle Type

Flash Bundle

20% OFF Number of Reports: 3

Small Business Bundle

25% OFF Number of Reports: 5

Growth Bundle

30% OFF Number of Reports: 8

Enterprise Bundle

35% OFF Number of Reports: 10
Overview
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 80 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 100 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards

*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*

Flash Bundle

Number of Reports: 3

20%

tax inclusive*

  • 3 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • Complimentary Excel Data Set
  • PPT Version of the Report
  • Power BI Dashboards
  • License Upgrade
  • Free Analyst Hours

Small Business Bundle

Number of Reports: 5

25%

tax inclusive*

  • 5 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • Complimentary Excel Data Set
  • PPT Version of the Report
  • Power BI Dashboards
  • License Upgrade

Growth Bundle

Number of Reports: 8

30%

tax inclusive*

  • 8 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • License Upgrade
  • Free Analyst Hours - 80 Hours
  • Power BI Dashboards

Enterprise Bundle

Number of Reports: 10

35%

tax inclusive*

  • 10 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • License Upgrade
  • Power BI Dashboards
  • Free Analyst Hours - 100 Hours

How To Order

This is a collaborative report by Vishakha Agrawal reflecting perspectives and research-driven insights from Expert Market Research.

Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.

License Type

Select License Type

Choose the right license for your needs and access rights.

shopping cart

Click on ‘Buy Now’

Add the report to your cart with one click and proceed to register.

Bookmark Icon

Select Mode of Payment

Choose a payment option for a secure checkout. You will be redirected accordingly.

Strategic Solutions for Informed Decision-Making

Connect For More Information

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.

Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.

We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.

We’re here to help answer any questions about our products and services.

Contact us